Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors

This is the authors' abstract. We don't add key points for this paper.

The formation of new blood vessels is crucial for tumor and metastatic progression. Consequently, targeted therapies directed toward the vascular endothelial growth factor (VEGF) pathway have significantly improved treatment outcomes in several malignancies. These treatment modalities are frequently used in current oncologic practice, as monotherapy or in combination with other anticancer regimens such as immune checkpoint inhibitors (ICIs), to enhance the anticancer effects. Despite their proven efficacy, anti-VEGF therapies are also known to cause substantial kidney toxicity. Common kidney side effects include hypertension, proteinuria, kidney dysfunction, thrombotic microangiopathy, and in some cases, kidney failure. These adverse effects pose significant challenges in clinical practice, as kidney damage can lead to lower dosing of anticancer treatment and compromise quality of life. The mechanisms underlying kidney toxicity associated with anti-VEGF therapies, including in combination with ICIs, are poorly understood. A deeper understanding of these mechanisms is essential for mitigating kidney damage and preserving kidney function during treatment. This review aims to explore the role of VEGF in kidney physiology, the incidence of kidney toxicities associated with anti-VEGF therapies, and the potential mechanisms driving these toxicities, with particular emphasis on the endothelin, nitric oxide, and prostanoid pathways. In addition, the review will address the kidney effects observed when anti-VEGF therapies are combined with ICIs, as both treatment modalities are independently associated with kidney-related adverse effects, along with the underlying mechanisms involved.